Sam Brusco, Associate Editor06.15.22
AI-powered cancer diagnostics firm Ibex Medical Analytics has earned CE mark approval for its Galen Gastric solution to support pathologists in detecting various types of gastric cancer.
The first-of-its-kind technology bolsters Ibex’s AI pathology solutions, allowing detection of cancer and other pathologies in gastric, breast, and prostate biopsies. There is a need for automated solutions and decision-support tools to help pathologists spot cancer more rapidly due to the overall increase of cancer incidence over the last few years.
The Galen Gastric integrated diagnostics solution supports gastric cancer, H. pylori, and other important clinical findings to shorten turnaround times and optimize workflows. To develop the solution, a team of pathologists, data scientists, and software engineers implemented deep learning tech and trained algorithms on over a million image samples scanned from digitized biopsy slides.
The CE mark follows a study that showed Galen Gastric had “very high accuracy” in detecting various types of gastric cancer, as well as Helicobacter pylori (H. pylori—a common gastric bacterial infection and a precursor for cancer), neuroendocrine lesions, dysplasia, adenoma and additional pathologies.
"We are proud to obtain this first-of-its-kind CE mark for AI-powered GI diagnostics in pathology, following excellent performance in a multi-site clinical study," Chaim Linhart, Ph.D., co-founder and CTO at Ibex, told the press. "We trained the Deep Learning models of Galen Gastric on more than a million image samples from multiple labs to ensure it can accurately detect not only cancer but also a multitude of other clinically relevant features that impact future treatment for patients. Ibex now offers an unprecedented breadth of clinical applications, and this approval will enable our growing customer base to expand the usage of AI technology and provide pathologists with new insights as they review gastric biopsies, improving the quality of cancer diagnosis and care."
The first-of-its-kind technology bolsters Ibex’s AI pathology solutions, allowing detection of cancer and other pathologies in gastric, breast, and prostate biopsies. There is a need for automated solutions and decision-support tools to help pathologists spot cancer more rapidly due to the overall increase of cancer incidence over the last few years.
The Galen Gastric integrated diagnostics solution supports gastric cancer, H. pylori, and other important clinical findings to shorten turnaround times and optimize workflows. To develop the solution, a team of pathologists, data scientists, and software engineers implemented deep learning tech and trained algorithms on over a million image samples scanned from digitized biopsy slides.
The CE mark follows a study that showed Galen Gastric had “very high accuracy” in detecting various types of gastric cancer, as well as Helicobacter pylori (H. pylori—a common gastric bacterial infection and a precursor for cancer), neuroendocrine lesions, dysplasia, adenoma and additional pathologies.
"We are proud to obtain this first-of-its-kind CE mark for AI-powered GI diagnostics in pathology, following excellent performance in a multi-site clinical study," Chaim Linhart, Ph.D., co-founder and CTO at Ibex, told the press. "We trained the Deep Learning models of Galen Gastric on more than a million image samples from multiple labs to ensure it can accurately detect not only cancer but also a multitude of other clinically relevant features that impact future treatment for patients. Ibex now offers an unprecedented breadth of clinical applications, and this approval will enable our growing customer base to expand the usage of AI technology and provide pathologists with new insights as they review gastric biopsies, improving the quality of cancer diagnosis and care."